Peroxisome proliferator activated receptor agonists
    3.
    发明授权
    Peroxisome proliferator activated receptor agonists 失效
    过氧化物酶体增殖物激活受体激动剂

    公开(公告)号:US07544812B2

    公开(公告)日:2009-06-09

    申请号:US10496770

    申请日:2002-11-26

    IPC分类号: A61K31/4166 C07D233/32

    摘要: The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4 alkyl sulfonamide, C1-C4 alkyl amide, OR10 and C3-C6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.

    摘要翻译: 本发明涉及由以下结构式(I)表示的化合物,(a)R 1选自氢,取代或未取代的选自C 1 -C 8烷基,芳基-C 0-4 - 烷基,杂芳基 C 0-4烷基,C 3 -C 6环烷基芳基-C 0-2 - 烷基和-CH 2 -C(O)-R 17 -R 18,其中R 17是O或NH,R 18是任选取代的苄基; (b)R 2选自C 1 -C 6烷基,C 1 -C 6烯基,芳基-C 0-4 - 烷基,杂芳基-C 0-4 - 烷基,C 1 -C 4烷基磺酰胺,C 1 -C 4烷基酰胺,OR 10 和C 3 -C 6环烷基; (c)W为O或S; (d)X是任选取代的C1-C5亚烷基连接体,其中连接体的一个碳原子可以任选地被O,NH,S取代,并且任选地两个碳可以一起形成双键; (e)Y选自C,O,S,NH和单键; 和(f)E选自C(R 3)(R 4)A,A和选自(CH 2)n COOR 19的取代或未取代的基团。

    Peroxisome proliferator activated receptor alpha agonists
    4.
    发明授权
    Peroxisome proliferator activated receptor alpha agonists 失效
    过氧化物酶体增殖物激活受体α激动剂

    公开(公告)号:US07205321B2

    公开(公告)日:2007-04-17

    申请号:US10495204

    申请日:2002-11-13

    IPC分类号: A61K31/4245 C07D271/10

    CPC分类号: C07D271/113

    摘要: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1–C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, and C3–C6 cycloalkylaryl-C0-2-alkyl; W is O or S; X is an optionally substituted C1–C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; Y is C, O, S, NH or a single bond; E is C(R3)(R4)A or A

    摘要翻译: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐,溶剂合物和水合物,R1选自氢,取代或未取代的基团,其选自C 1 -C 8烷基,芳基-C 0-4 - 烷基,杂芳基-C 0-4 - 烷基和C 3 -C 6环烷基芳基-C 0-2 - 烷基; W为O或S; X是任选取代的C1-C5亚烷基连接体,其中连接体的一个碳原子可被O,NH或S取代; Y是C,O,S,NH或单键; E为C(R3)(R4)A或A